CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Condensed Consolidated Statements Of Operations
Revenue		$ 41,000		$ 83,000
Operating costs:
Direct cost of revenue	4,000	65,000	7,000	127,000
General and administrative expenses	373,000	310,000	768,000	1,024,000
Research and development	21,000	(669,000)	52,000	155,000
Total operating costs and expenses	398,000	(294,000)	827,000	1,306,000
Loss from operations before other income and expenses	(398,000)	335,000	(827,000)	(1,223,000)
Other income and (expenses):
(Loss) on fair value adjustment of investments	(973,000)	203,000	(3,373,000)	203,000
Gain on deconsolidation of subsidiary		7,940,000		7,940,000
Interest and other expenses		96,000
NET INCOME (LOSS) INCLUDING NONCONTROLLABLE INTEREST	(1,371,000)	8,574,000	(4,199,000)	6,920,000
Net income (loss) attributable to noncontrolling interest		472,000
NET (LOSS) ATTRIBUTABLE TO MANHATTAN SCIENTIFICS, INC.	$ (1,371,000)	$ 9,046,000	$ (4,199,000)	$ 6,920,000
BASIC AND DILUTED INCOME (LOSS) PER COMMON SHARE:
Weighted average number of common shares outstanding (Basic)	533,781,064	533,781,064	533,781,064	533,781,064
Basic income (loss) per common share	$ (0.00)	$ 0.02	$ (0.01)	$ 0.01
Weighted average number of common shares outstanding (Diluted)	533,781,064	530,163,579	533,781,064	581,036,064
Diluted income (loss) per common share	$ (0.00)	$ 0.02	$ (0.01)	$ 0.01